Keyword Search
 
2017 | 2016
12/16/16

Aptevo Therapeutics Announces Publication of Phase 2 Clinical Data for Otlertuzumab

Data Show Improved Overall Response Rate and Progression Free Survival with Combination Otlertuzumab/Bendamustine Therapy SEATTLE, Dec. 16, 2016 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO) a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced the publication of positive data from a Phase 2 clinical trial evaluating its proprietary humanized monospecific anti-CD37 protein therapeutic, otlertuzumab. The results were recently pub...

Read More

12/15/16

Aptevo Therapeutics Amends Collaboration Agreement with MorphoSys AG for Novel Immunotherapeutic, MOR209/ES414

SEATTLE, Dec. 15, 2016 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO) a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that it has amended the terms of its collaboration agreement with MorphoSys AG, originally executed in August 2014, for the joint worldwide development and commercialization of MOR209/ES414, a novel bispecific immuno-oncology therapeutic currently being evaluated in a Phase 1 clinical study for the treatment ...

Read More

11/23/16

Aptevo Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare Conference

SEATTLE, Nov. 23, 2016 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that it will present at the 28th Annual Piper Jaffray Healthcare Conference on Wednesday, November 30, 2016 at 1:00 pm EST at the Lotte New York Palace Hotel. A live audio webcast of the presentation can be accessed at www.aptevotherapeutics.com under the ‘Investors’ section of the website, under ‘Events....

Read More

09/15/16

Aptevo Therapeutics Augments Leadership Team

Appoints Former GlaxoSmithKline Executive Randy Maddux  Senior Vice President, Operations Jane Gross, Ph.D., Promoted to Senior Vice President and Chief Scientific Officer SEATTLE, Sept. 15, 2016 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that Randy J. Maddux has joined the Company as Senior Vice President, Operations, effective July 2016.  Mr. Maddux brings more than 3...

Read More

08/05/16

Aptevo Therapeutics Closes $35 Million Term Loan Agreement

SEATTLE--(BUSINESS WIRE)--Aug. 5, 2016-- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that it has closed on a $35 million term loan agreement previously announced on August 1, 2016. “The $35 million term loan agreement further strengthens our balance sheet and provides additional operational flexibility at an attractive cost of capital,” st...

Read More

08/01/16

Aptevo Therapeutics Secures $35 Million Term Loan Agreement

SEATTLE--(BUSINESS WIRE)--Aug. 1, 2016-- Aptevo Therapeutics Inc. (“Aptevo”; “the Company”) (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that it has reached agreement with MidCap Financial on the final terms on a $35 million term loan. The agreement provides Aptevo with up to $35 million of available borrowing capacity, which will be available to the Company in two tranches of $1...

Read More

08/01/16

Aptevo Therapeutics Completes Separation from Emergent BioSolutions

SEATTLE--(BUSINESS WIRE)--Aug. 1, 2016-- Aptevo Therapeutics Inc. (“Aptevo”) (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today the completion of its separation from Emergent BioSolutions Inc. (“Emergent”) (NYSE: EBS) and its launch as an independent, publicly traded corporation. Aptevo common stock will begin "regular way" trading under the symbol “APVO” on the Nasdaq Global Se...

Read More

07/20/16

Emergent BioSolutions Announces Commencement of When Issued Trading of Aptevo Common Stock

GAITHERSBURG, Md., July 20, 2016 (GLOBE NEWSWIRE) -- In connection with the spin-off of Aptevo Therapeutics Inc. (Nasdaq:APVO) through a dividend distribution by Emergent BioSolutions Inc. (NYSE:EBS) of one share of Aptevo common stock for every two shares of Emergent common stock outstanding as of the close of business on July 22, 2016, Emergent announced that Aptevo common stock will commence trading today, July 20, 2016, on a "when issued" basis under the symbol "APVOV" on the Nasdaq Global S...

Read More

07/15/16

Emergent BioSolutions Announces Effectiveness of Aptevo Therapeutics Form 10 Registration Statement

Aptevo Therapeutics common stock approved for listing on the NASDAQ Global Select Market GAITHERSBURG, Md., July 15, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Registration Statement on Form 10 filed by Aptevo Therapeutics Inc. has been declared effective by the U.S. Securities and Exchange Commission. The Registration Statement on Form 10, available at www.emergentbiosolutions.com/spinoff, includes material information regarding Aptevo's business an...

Read More

07/11/16

Emergent BioSolutions’ Board of Directors Approves Spin-Off of Aptevo Therapeutics and Sets Record and Dividend Distribution Dates and Distribution Ratio

GAITHERSBURG, Md., July 11, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that, on July 10, 2016, its Board of Directors approved the spin-off of Aptevo Therapeutics Inc. and declared a dividend distribution of one share of Aptevo common stock for every two shares of Emergent common stock outstanding as of the close of business on July 22, 2016, the record date for the distribution. Emergent expects to complete the distribution of Aptevo common stock to Emergent ...

Read More

04/15/16

Emergent BioSolutions Announces Filing of Form 10 Registration Statement for Its Planned Spin-Off of Its Biosciences Business Aptevo Therapeutics

GAITHERSBURG, Md., April 15, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the initial filing of a Form 10 Registration Statement with the U.S. Securities and Exchange Commission in connection with the company's previously announced plan to spin-off certain assets of its biosciences business to create a separate, publicly-traded company, Aptevo Therapeutics Inc. The transaction is intended to qualify as a tax-free spin-off to the company's stockholders and is t...

Read More